Michael Quinn

Michael Quinn practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Michael Quinn's NPI, 1023513231, was assigned on March 28, 2018. Michael Quinn holds New Jersey license 25MB11440200.

Michael Quinn's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Michael Quinn's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. The medical group on file is Hackensack Meridian Medical Group. Dmand AI also links Michael Quinn to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Quinn practices. Vendor and product names are available with a free account.

Emergency medicine is Michael Quinn's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Michael Quinn is board certified in emergency medicine by the American Board of Emergency Medicine. Dmand AI has Michael Quinn's licenses on file in 2 states: New Jersey and New York.

CMS data shows 89 Medicare services from Michael Quinn across 3 procedure codes in 2024, for 88 Medicare patients. Medicare paid $12,015 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 88 Medicare patients who saw Michael Quinn in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael Quinn's median patient age at 52, with 56% women.

In 2024, Michael Quinn wrote 168 Medicare Part D claims for 95 patients. 95% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $542 in total drug cost. In 2023, CMS named 37 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Michael Quinn for performance year 2024, reported as part of a group. Michael Quinn accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 152 papers to Michael Quinn, published from 2006 to 2025. 2017 was the busiest year, with 12. The most frequent topics are Ovarian Neoplasms, Australia and Melanoma. Michael Quinn has published most often in Ann Surg Oncol. Michael Quinn's most frequent co-authors are Michael J. Quinn, MD, Jaswinder Singh Samra, MD and John F. Thompson, MD.

Dmand AI links Michael Quinn to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Endometrial Hyperplasia and Uterine Diseases.